Who are Kamal Therapeutics's investors?

Kamal Therapeutics's investors include Third Rock Ventures.

How much funding has Kamal Therapeutics raised?

Kamal Therapeutics has disclosed $23.8M raised across 2 rounds.

Where is Kamal Therapeutics headquartered?

Kamal Therapeutics is headquartered in Hingham, US.

Kamal Therapeutics

Hingham, US · Founded 2020 · Delaware corporation · 1 known investors

Kamal Therapeutics is developing an intravenous recombinant human decorin as a treatment for dystrophic epidermolysis bullosa. It operates as a biotechnology company focused on therapeutics for this genetic skin disorder.

Biotech Healthtech

Founders & leadership

Mark de SouzaExecutive

Alexander SilverNamed on SEC filing

Hal LandyNamed on SEC filing

Joff MasukawaNamed on SEC filing

Deborah RamsdellNamed on SEC filing

Board

Philip Reilly inBoard directorVenture Partner at Third Rock Ventures

John ParkerBoard director

Investors · 1

Third Rock VenturesreportedBoston · $100K – $5Mvia Philip Reilly · board

Reported raises · per SEC filings

Form D private placements

$23.8M disclosed across 2 rounds · 2021–2025

▶$13.8MraisedNov 2025 · 41 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Mark de SouzaExecutive Officer, Director
Philip ReillyDirector
John ParkerDirector

Offering amount: $17.3M
Amount sold: $13.8M
First sale: Nov 2025
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$9.9MraisedOct 2022 · 37 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Alexander SilverDirector
Hal LandyDirector
Joff MasukawaDirector
Deborah RamsdellExecutive Officer, Director
Mark P. de SouzaDirector

Offering amount: $10M
Amount sold: $9.9M
First sale: Aug 2021
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

FIBRX Derm - Cure EBcure-eb.org · Jan 2020

Frequently asked questions

What does Kamal Therapeutics do?: Kamal Therapeutics is developing an intravenous recombinant human decorin as a treatment for dystrophic epidermolysis bullosa. It operates as a biotechnology company focused on therapeutics for this genetic skin disorder.
Who are Kamal Therapeutics's investors?: Kamal Therapeutics's investors include Third Rock Ventures.
How much funding has Kamal Therapeutics raised?: Kamal Therapeutics has disclosed $23.8M raised across 2 rounds.
Where is Kamal Therapeutics headquartered?: Kamal Therapeutics is headquartered in Hingham, US.